Stocks Health care ABOS
NASDAQ · Health careAcumen Pharmaceuticals, Inc. (ABOS)
It posted a net loss of $104M. In fiscal 2025 capital spending exceeded operating cash flow by $115.6M. At September 30, 2026 it held $53.1M in cash against $5.9M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on October 26, 2026.
Key facts about Acumen Pharmaceuticals, Inc.
- Net worth
- Acumen Pharmaceuticals, Inc. has a market value (market cap) of $17.1M at the latest share price, and shareholders' equity of $34.6M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $115.5M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on October 26, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Acumen Pharmaceuticals, Inc.'s next report is expected around March 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Acumen Pharmaceuticals, Inc. does
Acumen Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker ABOS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$121.3M | -$2.00 | -$115.6M |
| 2024 | n/a | -$102.3M | -$1.71 | -$86.2M |
| 2023 | n/a | -$52.4M | -$1.08 | -$43.1M |
| 2022 | n/a | -$42.9M | -$1.06 | -$35.3M |
| 2021 | n/a | -$100.6M | -$5.02 | -$18M |
| 2021 | n/a | -$7.3M | -$17.48 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Acumen Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026
- October 30, 2026
- October 26, 2026
- October 26, 2026
- October 26, 2026
- September 16, 2026
- August 12, 2026
- August 12, 2026
- August 12, 2026
- June 16, 2026
Insider trades
What the people running Acumen Pharmaceuticals, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| June 17, 2026 | Porter DerrellDirector | Exercised options | 13,040 | $14K |
| June 17, 2026 | Porter DerrellDirector | Sold | 13,040 | $30.3K |
| June 16, 2026 | Porter DerrellDirector | Sold | 12,800 | $29.8K |
| June 15, 2026 | Porter DerrellDirector | Exercised options | 6,460 | $6.9K |
| June 15, 2026 | Porter DerrellDirector | Sold | 6,460 | $15.1K |
| June 9, 2026 | Fountain Nathan BDirector | Sold | 6,400 | $14.3K |
| June 3, 2026 | Ra Capital Management, L.P.Director, 10% owner | Received as payindirect | 35,500 | - |
| June 3, 2026 | Stoppel LauraDirector | Received as pay | 35,500 | - |
Who owns ABOS
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| RA Capital Management, L.P.13D, may seek influence with 3 related filers | 29.5% | March 17, 2026 |
| Sands Capital Alternatives, LLC13G, passive with 4 related filers | 5.6% | August 13, 2025 |
| James B. Murray Jr.13G, passive | 5% | April 7, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 96 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| RA Capital Management, L.P. | 20,992,669 | 0 |
| Sands Capital Alternatives, LLC | 3,720,105 | 0 |
| BlackRock, Inc. | 2,490,115 | +2,311,789 |
| Alyeska Investment Group, L.P. | 2,454,754 | 0 |
| Franklin Resources Inc | 2,305,096 | 0 |
| ADAR1 Capital Management, LLC | 2,111,334 | -45,000 |
| Vanguard Capital Management LLC | 1,672,072 | +165,795 |
| Knollwood Investment Advisory, LLC | 1,628,510 | 0 |
| Geode Capital Management, LLC | 1,141,858 | +725,620 |
| Ikarian Capital, LLC | 1,053,797 | 0 |
| Hudson Bay Capital Management LP | 955,000 | -13,940 |
| Pathstone Holdings, LLC | 859,110 | 0 |
| Renaissance Technologies LLC | 675,025 | +201,079 |
| Two Sigma Investments, LP | 622,882 | +92,070 |
| State Street Corp | 600,528 | +448,800 |
| Northern Trust Corp | 360,744 | +285,532 |
| Vanguard Portfolio Management LLC | 320,795 | new |
| Dimensional Fund Advisors LP | 291,559 | +171,803 |
| Vanguard Fiduciary Trust Co | 291,240 | +92,014 |
| Bank of America Corp | 274,781 | -45,435 |
Insiders
15 insiders reported holding 2,666,838 shares in total, about $632K at the last price.
| Holder | Shares |
|---|---|
| OConnell Daniel JosephChief Executive Officer, Director | 881,275 |
| Zuga MattCFO & Chief Business Officer | 304,924 |
| Siemers EricChief Medical Officer | 255,371 |
| Doherty James J.President and CDO | 220,900 |
| Stalfort John A IIIDirector | 220,624 |
| Barton RussellChief Operating Officer | 205,092 |
| Meisner Derek MChief Legal Officer & Corp Sec | 173,999 |
| Schacterle AmyChief Regulatory Officer | 92,303 |
| Ra Capital Management, L.P.Director, 10% owner | 48,30048,300 held indirectly |
| Drapkin Kimberlee CDirector | 48,300 |
Questions about ABOS
What does Acumen Pharmaceuticals, Inc. do?
Acumen Pharmaceuticals, Inc. is a company in the Health care sector, listed on NASDAQ as ABOS. Its shares trade on NASDAQ under the ticker ABOS.
What is Acumen Pharmaceuticals, Inc.'s net worth?
Acumen Pharmaceuticals, Inc. has a market value (market cap) of $17.1M at the latest share price, and shareholders' equity of $34.6M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Acumen Pharmaceuticals, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $104M.
When did Acumen Pharmaceuticals, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on October 26, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the material agreement ended from November 5, 2026.
When is Acumen Pharmaceuticals, Inc.'s next earnings report?
Acumen Pharmaceuticals, Inc.'s next report is expected around March 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ABOS with
Follow ABOS
Get an email when Acumen Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Acumen Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.